@article{50611bb65e5c4c19a731dea4e2009e6f,
title = "Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.",
author = "Flinn, \{Ian W.\} and Cherry, \{Mohamad A.\} and Maris, \{Michael B.\} and Matous, \{Jeffrey V.\} and Berdeja, \{Jesus G.\} and Manish Patel",
note = "Duvelisib, a potent δ- and γ-PI3K inhibitor, is a potential therapeutic for hematologic malignancies. Rituximab and bendamustine have demonstrated activity in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Combining duvelisib with either rituximab alone or rituximab and bendamustine may improve response rates and remission durability.",
year = "2019",
month = dec,
day = "1",
doi = "10.1002/AJH.25634",
language = "American English",
volume = "94",
journal = "American Journal of Hematology",
issn = "1096-8652",
publisher = "Wiley-Blackwell",
number = "12",
}